Subarachnoid haemorrhage with negative initial neurovascular imaging: a systematic review and meta-analysis. by Mohan, Midhun et al.
REVIEW ARTICLE - VASCULAR NEUROSURGERY - OTHER
Subarachnoid haemorrhage with negative initial neurovascular
imaging: a systematic review and meta-analysis
MidhunMohan1 & Abdurrahman I. Islim1 & Fahid T. Rasul2 & Ola Rominiyi3 & Ruth-Mary deSouza4 & Michael T. C. Poon5 &
Aimun A. B. Jamjoom6 & Angelos G. Kolias7 & Julie Woodfield6 & Krunal Patel8 & Aswin Chari9,10 & Ramez Kirollos7 &
British Neurosurgical Trainee Research Collaborative
Received: 20 May 2019 /Accepted: 25 July 2019 /Published online: 13 August 2019
# The Author(s) 2019
Abstract
Background In patients with spontaneous subarachnoid haemorrhage (SAH), a vascular cause for the bleed is not always found
on initial investigations. This study aimed to systematically evaluate the delayed investigation strategies and clinical outcomes in
these cases, often described as “non-aneurysmal” SAH (naSAH).
Methods A systematic review was performed in concordance with the PRISMA checklist. Pooled proportions of primary
outcome measures were estimated using a random-effects model.
Results Fifty-eight studies were included (4473 patients). The cohort was split into perimesencephalic naSAH (PnaSAH)
(49.9%), non-PnaSAH (44.7%) and radiologically negative SAH identified on lumbar puncture (5.4%). The commonest initial
vascular imaging modality was digital subtraction angiography. A vascular abnormality was identified during delayed investi-
gation in 3.9% [95%CI 1.9–6.6]. There was no uniform strategy for the timing or modality of delayed investigations. The pooled
proportion of a favourable modified Rankin scale outcome (0–2) at 3–6 months following diagnosis was 92.0% [95% CI 86.0–
96.5]. Complications included re-bleeding (3.1% [95% CI 1.5–5.2]), hydrocephalus (16.0% [95% CI 11.2–21.4]), vasospasm
(9.6% [95% CI 6.5–13.3]) and seizure (3.5% [95% CI 1.7–5.8]). Stratified by bleeding pattern, we demonstrate a higher rate of
delayed diagnoses (13.6% [95% CI 7.4–21.3]), lower proportion of favourable functional outcome (87.2% [95% CI 80.1–92.9])
and higher risk of complications for non-PnaSAH patients.
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Conclusion This study highlights the heterogeneity in delayed investigations and outcomes for patients with naSAH, which may
be influenced by the initial pattern of bleeding. Further multi-centre prospective studies are required to clarify optimal tailored
management strategies for this heterogeneous group of patients.
Keywords Meta-analysis . Non-aneurysmal . Subarachnoid haemorrhage . Systematic review
Introduction
Spontaneous subarachnoid haemorrhage (SAH) is a life-
threatening condition most commonly caused by the rupture
of an intracranial aneurysm [18, 49]. Once SAH has been
confirmed, dedicated cerebrovascular imaging is performed
to establish if there is an underlying vascular abnormality.
CT angiography (CTA) is the most common initial cerebro-
vascular imaging modality used in the UK and Ireland [22],
although digital subtraction angiography (DSA) is considered
the gold standard [79]. Early detection of vascular abnormal-
ities is important to direct timely treatment [23].
In up to 15% of patients with spontaneous SAH, a struc-
tural cause for the bleeding is not identified on initial vascular
imaging [23], and these are said to have experienced a non-
aneurysmal SAH (naSAH). This group is heterogeneous and
can be categorised into three subgroups, based on the distri-
bution of blood on the initial non-contrast CT scan [70]:
& Perimesencephalic (PnaSAH): Defined as “blood present
anterior to the midbrain with or without extension to the
anterior ambient cistern or basal Sylvian fissure and with-
out complete filling of the interhemispheric fissure or ex-
tension to the lateral Sylvian fissure”.
& Non-perimesencephalic (non-PnaSAH): Acute blood is seen
on the CT scan that is not confined to the PnaSAH territory.
& Radiologically negative: No acute blood on the CT scan.
Diagnosis is made by spectrophotometric detection of a
bilirubin peak in cerebrospinal fluid from a lumbar punc-
ture (LP).
Although commonly accepted that patients with naSAH
experience a “better” clinical course than aneurysmal SAH
patients [23, 76], there is uncertainty regarding the functional
outcomes and complications in these patients.
There also appears to be a wide variation in the investiga-
tion, follow-up and delayed pick-up rate of vascular abnor-
malities in naSAH patients [55]. This is particularly important
since, although DSA is the gold-standard investigation, it rep-
resents an invasive procedure that is not without risk of com-
plications [16]. Furthermore, subjecting a patient to multiple
DSAs needs to be weighed carefully against the benefits and
probability of identifying a cause for the bleed. Since CTA has
become the first-line investigation, the added value of conven-
tional DSA in these patients has also not been firmly
established [29].
Objectives
This systematic review and meta-analysis aimed to summarise
the literature on the investigation andmanagement of naSAH by:
i. Synthesising estimates of complications risk and function-
al outcomes reported to date.
ii. Collating and comparing the various neurovascular imag-
ing strategies and delayed diagnoses rates reported for this
cohort of patients.
Methods
This systematic review was registered with PROSPERO
(CRD42016035376) and has been reported in accordance
with the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement [46].
Search strategy
Medline, Web of Knowledge, Embase and the Cochrane
Database of Systematic Reviews, via the National Institute’s
for Health and Care Excellence Health Databases Advanced
Search (NICE HDAS) function, were inspected. The search
strategy utilised was as follows:
i . (“non aneurysmal” OR “non-aneurysmal” OR
“perimesencephalic” OR “angiogram-negative” OR “an-
giogram negative”).
ii. (“subarachnoid hemorrhage” OR “subarachnoid haemor-
rhage” OR “SAH”).
iii. i AND ii.
The bibliographies of accepted papers were examined for
additional articles not identified in the initial search. The
search was last updated in April 2018.
Study selection
The resulting titles and abstracts were screened independently
by two authors (M.M. and O.R.) using the patients, interven-
tion, comparator, outcomes and study design (PICOS) criteria
below. All decisions about an article’s inclusion or exclusion
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were blinded. Where disagreements occurred, a senior author
(A.C.) was consulted.
PICOS criteria
& Patients: Adults (≥ 16 years) with a diagnosis of spontaneous
SAH (either by CT brain or LP) and negative initial
neurovascular imaging. The term “initial vascular imaging”
was defined as one or more dedicated cerebrovascular imag-
ing techniques (CTA, magnetic resonance angiography
[MRA] or DSA) performed within 72 h of ictus. If no
time-period was specified in the study, but the study stated,
“initial imaging”, this was taken as the form of initial imag-
ing strategy used. Traumatic SAH was excluded.
& Interventions/Comparators: Not required.
& Outcomes:
i. Primary: Functional outcomes at 6 months post-ictus.
ii. Secondary: Functional outcomes at discharge and ≥
1 year post-ictus, delayed diagnoses (including timing
and modality of imaging that detected the abnormali-
ty), complications (re-bleeding, hydrocephalus, vaso-
spasm, seizure or serum sodium (Na+) abnormality
[hypo- and hypernatremia]), length of hospital stay,
cost and patient perception of information provided
by clinical team. Delayed diagnosis was defined as
the diagnosis of an aneurysm or any other vascular
abnormality that could explain the initial bleed, not
identified by the initial vascular imaging strategy but
subsequently identified on repeat imaging.
& Study design: Full-text English-language publications of
studies with ≥ 10 patients.
Data extraction
Demographics data, presenting bleeding pattern (PnaSAH,
non-PnaSAH, radiologically negative) and initial
neurovascular imaging strategies were extracted independent-
ly by two authors (M.M. and O.R.) using a standardised
proforma, with disagreements resolved via further review
and discussion with a senior author (A.C.).
Data synthesis
Presenting clinical-radiological status
The initial clinical grade recorded either using the World
Federation of Neurosurgical Societies (WFNS) or Hunt
and Hess grading system, and radiological grade via
Fisher or the modified Fisher grading system were noted.
For pooled analyses, both clinical measures were
dichotomised into good (grades 1–3) and poor (grades
4–5) and modified Fisher grades were translated back into
the original grading system (Modified Fisher 0 ➔ Fisher
1, 1 ➔ 2, 3 ➔ 3, 2 & 4 ➔ 4).
Functional outcomes
These were examined at three time-points—at discharge (or
early outcome), 3–6 months and at ≥ 1 year. Outcomes were
dichotomised into favourable (modified Rankin scale [mRS]
0–2) and unfavourable (mRS 3–6).
Post-naSAH complications
Re-bleeding was split into early (prior to discharge or <
14 days) and late based on the common definitions used by
the included studies. Hydrocephalus requiring surgical inter-
vention was categorised into temporary (requiring temporary
external ventricular drainage only) and long term (requiring
CSF shunting). Vasospasm was sub-divided into radiological
and clinical (i.e. delayed ischemic neurological deficit
[DIND]).
Statistical analysis
Study-level data were collated and presented as number (per-
centage), mean (standard deviation [SD]) or median (inter-
quartile range [IQR]) as appropriate. For each outcome of
interest, the primary summary statistic extracted from the in-
cluded studies was the incidence risk or proportion (number of
events/total number of patients). To obtain an overall summa-
ry statistic (95% confidence interval [95% CI]), the following
steps were followed:
i. The proportions of the included studies were transformed
using the Freeman-Tukey double arcsine method [26].
This allowed for normalisation and variance stabilisation
of data with a binomial distribution and enabled the use of
studies with null event rates as to represent the whole study
population.
ii. Transformed proportions were combined using an
inverse-variance weighted random-effects meta-analy-
sis model as described by DerSimonian and Laird
[19]. For ease of interpretation, the aggregated num-
ber of the transformed proportions was converted
back to the original scale (inverse-variance). To ac-
count for suspected methodological variation and
population diversity, a random-effects model, which
assumes unequal variance between studies, was used
to distribute statistical weighting more conservatively;
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small studies were not discounted, and larger studies
were less likely to dominate the analysis.
Variation across studies, owing to heterogeneity rather than
chance, was estimated using the I2 statistic and categorised
into low (≤ 25%), moderate (~ 50%) and high (≥ 75%).
SPSS ® v24.0 and StatsDirect ® v3.0 were used for statistical
analyses.
Quality assessment
The NIH Quality Assessment Tool for Observational Cohort
and Cross-Sectional Studies was used to assess risk of bias
(Fig. e-1). All quality assessments were undertaken in a
blinded fashion by two authors (M.M. and A.I.I.). Where dis-
crepancies arose, a third author (A.C.) was consulted.
Results
A total of 58 studies were included, totalling 4473 patients
(Fig. 1). Of these, 19 were prospective [1, 2, 9, 10, 20, 21, 32,
38, 39, 41–44, 47, 48, 50, 51, 53, 54], 37 were retrospective [4,
6–8, 12–15, 17, 24, 25, 27, 28, 30, 31, 34–36, 40, 57, 58, 61, 63,
66–69, 71–76, 78, 80–82] and two studies [11, 52] had both
prospective and retrospective data (Table e-1). Quality assess-
ment results are summarised in Fig. e-2. Three studies (5.17%)
were “poor”, 31 (53.4%) were “fair” and 24 (41.4%) were
“good”.
Demographics and pattern of bleeding
Among the 49 studies (3853 patients) in which demographic
data were reported, the weighted mean age of included sub-
jects was 53.8 years. Forty-five studies (3493 patients)
Fig. 1 PRISMA flow chart
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reported sex and 54.3% were male (Table e-1). Forty-five
studies (3530 patients) sub-classified naSAH by pattern of
bleeding; 49.9% (1763/3530) patients had a PnaSAH, 44.7%
(1577/3530) patients had a non-PnaSAH and 5.4% (190/
3530) had radiologically negative SAH.
Pooled proportions of presenting WFNS grade, Hunt and
Hess grade and Fisher grade are shown in Fig. 2. A higher
proportion of non-PnaSAH patients had poor presenting clin-
ical and radiological grade.
Initial vascular imaging and delayed diagnoses
The initial vascular imaging strategies, reported in 50 studies,
were heterogenous—DSA only (64%), CTA + DSA (16%),
DSA + MRA (6%), CTA + DSA + MRA (6%), CTA only
(4%) and DSA or CTA (4%).
Eighteen studies reported delayed diagnoses data. From a
total of 1965 patients, 89 patients were found to have a vas-
cular abnormality at a delayed investigation (range from 0 to
17.3%; Table e-2), yielding a pooled proportion of 3.9% [95%
CI 1.9–6.6, I2 = 85.6%] (Fig. 3). Details regarding the timing
of the delayed imaging are available in Table e-2; timing was
not reported in 14/18 (77.8%) studies and the earliest and
latest investigations in the four other studies were reported at
≤ 72 h and ≥ 1 year from ictus. Anterior circulation aneurysm
(60.6%) was the most commonly reported diagnosis (Table 1).
The pooled rate of delayed diagnoses was 3.9% when
DSA alone was the initial vascular imaging strategy,
1.7% when DSA and CTA were used and 7.8% when
DSA and MRI/A (including spine) were used (Fig. 4).
No studies reported delayed diagnoses data following
CTA alone. The modality on which the delayed diagno-
ses were identified was DSA in most of the cases, al-
though some were also identified on CTA (Fig. 4).
Seven studies reported delayed diagnoses stratified by
bleeding pattern: 3.5% [95% CI 1.0–7.5, I2 = 28.3%]
for PnaSAH and 13.6% [95% CI 7.4–21.3, I2 =
74.3%] for non-PnaSAH. One study reported a single
abnormality found on delayed imaging in 10 patients
with radiologically negative SAH (10.0%).
Functional outcomes
Functional outcomes were reported in 17/58 studies (1402 pa-
tients). At discharge, outcomes were available for 273 patients (5
studies) and 177 had a favourable outcome (pooled proportion
86.5% [95% CI 80.3–91.6, I2 = 61.6%]). At 3–6 months, 685/
774 patients (7 studies) had a favourable outcome (pooled pro-
portion 92.0% [95% CI 86.0–96.5, I2 = 85.1%]). Two studies
(190 patients) reported long-term outcomes (≥ 1 year); 171 had
a favourable outcome (pooled proportion 89.6% [95% CI 86.6–
97.1, I2 = 0%]). Outcomes stratified by bleeding pattern highlight
that the likelihood of a poor outcome at 3–6months and ≥ 1 year
was double in non-PnaSAHpatients when compared to PnaSAH
patients (Fig. 5).
Complications and length of hospital stay
Complications data were reported in 37/58 studies (3133
patients). Re-bleeding was reported in 23/58 studies
(1675 patients) with a pooled risk of 3.1% [95% CI
1.5–5.2]. Hydrocephalus was reported in 28 studies
(2399 patients) and the pooled risk was 16.0% [95%
CI 11.2–21.4]. The pooled risk of vasospasm, reported
in 19 studies (1926 patients), was 9.6% [95% CI 6.5–
13.3]. Five studies (379 patients) reported incidence of
seizures with a pooled risk of 3.5% [95% CI 1.7–5.8],
although they did not specify whether these were early
or late. The pooled risk of Na+ abnormalities, available
in eight studies (547 patients), was 2.7% [95% CI 0.6–
6.2]. Stratified by pattern of bleed, the risk of the
above-mentioned complications in non-PnaSAH patients,
except for Na+ abnormalities, was about double that of
the PnaSAH cohort (Table 2).
Nine studies (608 patients) reported data regarding length
of stay (Table 3) with the shortest median and mean for pa-
tients with PnaSAH being 10 and 8.3 days, respectively. For
patients with non-PnaSAH, the shortest median and mean
were 8.3 and 4 days, respectively. One study reported a medi-
an length of stay of 5 days for patients with radiologically
negative SAH. The heterogeneity of formats in the reporting
of length of stay means that meta-analysis could not be
performed.
Additional outcomes
No data were available in the included studies to inform two
outcomes that were stated in our protocol, namely cost and pa-
tient perception of information provided by the clinical team.
Table 1 Delayed diagnoses details available for 66 patients
Diagnosis N (%)
Anterior circulation aneurysm 40 (60.6)
Posterior circulation aneurysm 15 (22.7)
Aneurysma 2 (3.0)
Posterior circulation pseudoaneurysm 2 (3.0)
Infundibuluma 2 (3.0)
Spinal AVMa 1 (1.5)
Brain AVMa 1 (1.5)
Brain cavernomaa 1 (1.5)
Vertebral artery dissection 1 (1.5)
AV fistulaa 1 (1.5)
AV arteriovenous, AVM arteriovenous malformation
a Location unspecified
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Fig. 2 a Presenting Fisher grade stratified by bleeding pattern. Pooled
percentages were informed by three studies (350 patients). b Presenting
WFNS and Hunt and Hess grades stratified by bleeding pattern. Pooled
WFNS percentages were informed by nine studies (594 patients). Pooled
Hunt and Hess percentages were informed by 19 studies (1545 patients)
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Discussion
This systematic review highlights the heterogeneity in presen-
tation, functional outcomes and frequency of delayed diagno-
ses of naSAH patients, which, given its increasing incidence
[37], emphasises a need to clarify optimal management strat-
egies. Specifically, it is an important step in highlighting the
need for tailored management that takes into consideration the
higher rate of delayed diagnoses and complications in the non-
PnaSAH cohort.
This review raises several interesting findings. The primary
outcome of interest in our protocol was functional outcome at
6 months post-ictus as we sought to better understand out-
comes in a group of patients who are generally thought to
have “good” functional outcomes. The results suggest that
non-PnaSAH patients had double the proportion of
unfavourable outcomes at 3–6 months (12.8 vs 6.1%) and ≥
1 year (14.4 vs 7.3%) when compared to PnaSAH patients and
higher rate of complications including re-bleeding (3.5 vs
1.1%), hydrocephalus (25.5 vs 9.0%), vasospasm (13.5 vs
6.9%) and seizures (5.2 vs 2.5%); interestingly, the rates of
sodium abnormalities were similar between the groups (2.2 vs
2.3%). This subgroup of patients may benefit from early trans-
fer to a neurosurgical unit for the prevention and management
of potential complications. This closely mirrors the findings of
other publications, which suggest similar outcome and com-
plication rates to patients with aneurysmal SAH [3]. There is
evidence that, even in PnaSAH, patients may have cognitive
or neuropsychogical impairment that precludes return to their
premorbid functional state [50, 59]. Some of these patients
may require specialised neurological rehabilitation and iden-
tification of the long-term neuropsychological, cognitive and
quality-of-life outcomes is clearly warranted. Identification of
these outcomes may also have implications for resource pro-
vision in terms of longer-term neurological rehabilitation.
It also shows that clinicians use diverse neurovascular in-
vestigation strategies before classifying patients as “non-an-
eurysmal”. A large proportion of studies utilised DSA as part
of the first-line strategy and only two studies used CTA solely
as the initial imaging tool, both of which did not report their
rates of delayed diagnoses. Contemporary practice commonly
involves CTA as a first-line investigation, which has been
shown to have high specificity and sensitivity [77]. In addi-
tion, the potential risks of a DSA need to be considered but
Fig. 3 Forest plot showing the
risk of delayed diagnosis (95%
CI). Horizontal lines denote 95%
CIs; solid squares represent the
point estimate of each study and
the diamond represents the pooled
proportion of delayed diagnoses
(3.9% [95% CI 1.9–6.6, I2 =
85.6%]). The size of the solid
squares is proportional to the
weight of the study
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were not reported by any of the studies in this review. In an era
of centralised neurosurgical and neuroradiological services
and high quality CTA, it seems pertinent to evaluate the added
benefits of early DSA (which requires transfer of patients to
regional neurosciences centre) if the patient has a low-risk
pattern of bleeding (i.e. PnaSAH) and the initial CTA is of
sufficient quality and does not identify a vascular abnormality
[5]. The studies included in this review did not permit such an
assessment. It is interesting, however, to note that the delayed
pick-up rate of vascular abnormalities in patients who had had
a CTA and DSA as their initial strategy was as low as 1.7%.
Another poorly understood entity in acute SAH, especially
in the context of a negative CTA, is the role of early MR
imaging, including MRA and spinal imaging. Interestingly,
our study identified a high delayed diagnosis rate of 7.8% in
patients who had had initial DSA and MRI/A and the reasons
behind this warrant further exploration. A recent study
showed high sensitivities (98.2%) but slightly lower specific-
ities (91%) of 3.0 T MRA in detecting vascular abnormalities
in a large cohort of acute good-grade SAH patients, indicating
that it could be a useful tool even in the acute setting [45].
To our knowledge, there are no published guidelines as to
which imaging modalities to use for repeat imaging and the
timeframe for when this repeat imaging should be undertaken.
We found that delayed diagnoses were almost 4× more prev-
alent in the non-PnaSAH group compared to the PnaSAH
group and so it would seem logical to investigate patients with
non-PnaSAH more comprehensively and as early as possible
to facilitate early treatment of vascular abnormalities, avoid
re-bleeding events and thereby optimise functional outcomes.
Other risk factors for delayed diagnosis, that warrant early
aggressive investigation, also require characterisation. It is
interesting to note that the majority of delayed diagnoses were
identified on follow-up DSA, although this may simply be a
consequence of DSA being the predominant investigation
used in the delayed setting; the yield of non-invasive tech-
niques in this delayed setting also requires evaluation. For
the time-being, and in view of the marked heterogeneity of
Fig. 4 Risk of delayed diagnosis stratified by initial investigation strategy and details of imaging modalities by which delayed diagnoses were identified
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initial investigation regimens, and the poor reporting of timing
of delayed imaging and diagnoses, specific recommendations
regarding follow-up imaging cannot be made and tailored to
each bleeding pattern.
These data make a strong case for a large-scale multi-centre
prospective observational studies to better understand the nu-
ances of delayed diagnoses, functional outcomes and compli-
cations in patients with naSAH. Studying a large consecutive
prospective cohort with individual patient-level data will al-
low inferences to be made about the utility of various imaging
modalities, particularly if Bayesian statistical models are in-
corporated, which allow assessments of probabilities of spec-
ified outcomes (functional outcome, complication, delayed
diagnosis) based on priors. This will then enable us to formu-
late nuanced individualised strategies that optimise patient
outcomes allowing stratification of patients that may require
Table 3 Details regarding length of stay (days) for patients with naSAH stratified by pattern of bleed
Study Overall, N LOS PnaSAH, N LOS Non-PnaSAH,N LOS Radiologically
negative, N
LOS
Georgen et al., 1993 18 NR 9 12a NR NA NR NA
Andaluz et al., 2008 92 6.3b 45 4.3b 47 8.3b 0 NA
Beseoglu et al., 2010 21 15.3b 12 11.2b 9 20.7b 0 NA
Nayak et al., 2010 190 14c NR NA NR NA NR NA
Delgado Almandoz et al., 2012 25 2–7a 15 2–7a 8 2–7a 2 2–7
34 8–14a 12 8–14a 20 8–14a 2 8–14
13 ≥ 15a 2 ≥ 15a 11 ≥ 15a 0 ≥ 15
Boswell et al., 2013 31 NR 14 12.5b 16 13.2b 1 NR
Khan et al., 2013 50 NR 17c 8.3 23c 10 10c 5
Muehlschlegel et al., 2013 93 11c 36 NR 48 NR 9 NR
Canneti et al., 2015 41 21.1b 17 17b 24 24b 0 NA
LOS length of stay, NA not applicable, NR not reported
a Discharged within
bMean
cMedian
Fig. 5 Modified Rankin scale outcomes stratified by bleeding pattern
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early and/or delayed angiography, or management of acute or
chronic neurological complications. Furthermore, economic
analyses need to be undertaken to specifically address the
issue of patient transfers to specialist neuroscience units for
further investigation and management, an aspect that was not
reported in any of the included studies.
Perhaps an under-appreciated aspect is the patient perspec-
tive; these patients are often left with a sense of uncertainty
surrounding their prognosis and need for further investigation
and interventions [65], although these were not reported in
any of the studies included in this review. Therefore, studying
what information is conveyed to the patient also seems pru-
dent; specifically, in an era of shared decision making, the
presentation of the risk-benefit balance and the involvement
of the patient and family in the decision-making process be-
comes all the more important.
Some limitations of this study should be noted. Most stud-
ies included were single-centre retrospective studies, limited
by inherent biases. This reflected in the highly heterogeneous
meta-analyses and quality assessment results, and as such,
caution should be exercised in interpretation of pooled pro-
portions. However, given that the majority of the studies in
this field are retrospective, of which somewere assessed in our
quality assessment tool as “good”, we chose to continue to
include these in the systematic review and meta-analysis.
Especially in a field with high heterogeneity, we found evi-
dence that including multiple study designs is warranted [64].
Furthermore, radiological breakdown of non-PnaSAH into
cortical or basal cistern patterns was not feasible with the data
available. Timing between ictus and CT was not extracted.
SAH blood normally resorbs over time, and a scan at 72 h
suggesting a PnaSAH may well represent the residual blood
from a non-PnaSAH. The data is also historical, with many of
the studies using DSA as the initial imaging modality; it
would be prudent to assess the prevalence of naSAH and
delayed diagnosis rates in an era of widespread use of high-
resolution CTA. It was not within the scope of this review to
determine the diagnostic accuracy of the different imaging
modes of a diagnostic modality and as such data regarding
resolution among other imaging parameters were not extract-
ed. Risk of complications of CTA, DSA and MRI/A was not
determined based on data available in our selected studies;
however, this is an important aspect to consider against the
risk of delayed diagnosis in naSAH patients and particularly
those with a perimesencephalic pattern.
Heterogeneity and external validity
The strengths of this study with regard to external validity
include the large pooled population from diverse geographical
locations, the primarily uniform definitions to describe groups
of bleeding pattern and the agreement with previous studies
on the association between bleeding pattern and delayed
diagnoses outcomes [33, 56, 62]. However, the reliability of
our results is dependent on the quality of data available in the
included studies, and selection and recall bias may influence
the generalisability of our findings; data was pooled from
populations with differing and often unknown baseline char-
acteristics, for example, data regarding use of antiplatelet and
anticoagulant drugs were not available. Furthermore, possible
interactions among variables associated with post-bleed com-
plications and functional outcomes, such as clinico-
radiological severity and bleeding pattern, could not be
accounted for as the nature of the data available precluded
multivariate or individual patient-level analyses. Significant
variation in outcome measures was also observed. All of these
are reflected in the large I2 values in many of the meta-analy-
ses, and therefore, caution should be exercised in interpreting
some of these results. These limitations and high I2 statistics
highlight the fact that there is significant heterogeneity within
the pre-defined subgroups and suggest that decisions about
management and further investigation require large volumes
of individual patient-level data from carefully curated pro-
spective databases to understand the nuances of how to tailor
management to detect occult vascular causes and optimise
functional outcomes. There is also a clear need to report stud-
ies according to the newly developed set of common data
elements and develop a patient-centred core outcome set for
data standardisation to allow future homogenous analyses that
will benefit both patients and clinicians [60].
Conclusions
There is much heterogeneity in how patients with spontaneous
SAH and negative initial angiographic imaging are investigat-
ed and treated. Although there are a higher proportion of pa-
tients with favourable functional outcome in the PnaSAH co-
hort compared to the non-PnaSAH cohort, both cohorts have
patients (6.1 and 12.8%, respectively) with unfavourable func-
tional outcomes that may be optimised with better acute man-
agement of complications and longer-term rehabilitation.
There is a higher rate of delayed diagnoses in the non-
PnaSAH cohort. However, with the heterogeneity of initial
and delayed neurovascular imaging strategies, it is challeng-
ing to attribute the delayed discovery to a single patient aspect,
be it clinical or radiological. This systematic review therefore
highlights the need for an evidence-based, stratified approach
to this patient cohort based upon the initial pattern of bleeding
and clinico-radiological status. There is a pressing need for a
contemporary large-scale prospective multi-centre observa-
tional study that would facilitate the identification of high-
risk patients that require comprehensive investigation and
management in neuroscience centres with specific
neurorehabilitation requirements and potentially low-risk pa-
tients that can be managed with more conservative strategies.
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